Maze Therapeutics CEO reports 34,501-share stock sale

Maze Therapeutics, Inc. Chief Executive Officer Jason V. Coloma reported indirect sales totaling 34,501 shares of common stock on August 3, 2026.

Rhea-AI Filing Summary

Maze Therapeutics, Inc. Chief Executive Officer Jason V. Coloma reported indirect sales totaling 34,501 shares of common stock on August 3, 2026. Shares held by The Coloma 2021 Irrevocable Trust and the Coloma Family Trust, for which Coloma and his spouse are co‑trustees, were sold in four non‑derivative transactions at weighted average prices of $26.7145, $27.0940, $26.7140, and $27.0853 per share, executed pursuant to a Rule 10b5‑1 trading plan adopted on February 6, 2026.

Insider Trade Summary 10b5-1

Net Seller: 34,501 shares

Net Sell 4 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 34,501 shs ($922K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	2,439	$26.7145	$65K
Sale	Common Stock F1, F4, F3	154	$27.094	$4K
Sale	Common Stock F1, F5, F6	30,304	$26.714	$810K
Sale	Common Stock F1, F7, F6	1,604	$27.0853	$43K

Holdings After Transaction: Common Stock — 20,744 shares (Indirect, The Coloma 2021 Irrevocable Trust); Common Stock — 255,263 shares (Indirect, Coloma Family Trust)

Footnotes (7)

1. F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
2. F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4, 5, and 7 of this Form 4.
3. F3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.
4. F4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.16 per share, inclusive.
5. F5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.005 to $26.985 per share, inclusive.
6. F6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.
7. F7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.19 per share, inclusive.

Key Figures

Total shares sold: 34501 shares Shares sold by The Coloma 2021 Irrevocable Trust: 2439 shares Additional shares sold by The Coloma 2021 Irrevocable Trust: 154 shares +3 more

6 metrics

Total shares sold 34501 shares Aggregate common stock sold indirectly on August 3, 2026

Shares sold by The Coloma 2021 Irrevocable Trust 2439 shares Non-derivative sale of common stock at $26.7145 per share

Additional shares sold by The Coloma 2021 Irrevocable Trust 154 shares Non-derivative sale of common stock at $27.0940 per share

Shares sold by Coloma Family Trust 30304 shares Non-derivative sale of common stock at $26.7140 per share

Additional shares sold by Coloma Family Trust 1604 shares Non-derivative sale of common stock at $27.0853 per share

Price range for first trust sale $26.01–$26.97 per share Range of individual trade prices underlying weighted average in footnote F2

Key Terms

Rule 10b5-1 trading plan, weighted average price, Irrevocable Trust, co-trustees

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The reported price in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Irrevocable Trust other

"These securities are directly held by The Coloma 2021 Irrevocable Trust"

An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.

co-trustees other

"for which the reporting person and his spouse serve as co-trustees."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider stock transactions did Maze Therapeutics (MAZE) report for Jason V. Coloma?

Maze Therapeutics CEO Jason V. Coloma reported indirect sales totaling 34,501 common shares on August 3, 2026. Four non-derivative transactions involved 2,439 and 154 shares from The Coloma 2021 Irrevocable Trust and 30,304 and 1,604 shares from the Coloma Family Trust.

Were Jason V. Coloma’s MAZE stock sales made under a Rule 10b5-1 plan?

Yes. The reported transactions were effected under a Rule 10b5-1 trading plan adopted on February 6, 2026. A plan-based structure means trades follow pre-set instructions rather than ad hoc decisions about timing.

At what prices were Maze Therapeutics (MAZE) shares sold in these insider transactions?

The reported weighted average sale prices were $26.7145, $27.0940, $26.7140, and $27.0853 per share. Footnotes explain these averages reflect multiple trades within price ranges such as $26.01–$26.97 and $27.04–$27.19 per share.

How were the sold Maze Therapeutics (MAZE) shares held for Jason V. Coloma?

All reported MAZE shares were held indirectly through trusts. The Coloma 2021 Irrevocable Trust and the Coloma Family Trust directly held the securities, with Coloma and his spouse serving as co-trustees, so transactions are attributed to these entities.

How many Maze Therapeutics (MAZE) transactions and shares were involved overall?

The insider report shows four non-derivative transactions involving an aggregate of 34,501 common shares of Maze Therapeutics. Each entry reflects an indirect sale by one of the Coloma-related trusts, rather than a direct personal holding by Jason V. Coloma.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:09 PM Accepted by SEC EDGAR 08/05/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/03/2026		S(1)		2,439	D	$26.7145(2)	20,898	I	The Coloma 2021 Irrevocable Trust(3)
Common Stock	08/03/2026		S(1)		154	D	$27.094(4)	20,744	I	The Coloma 2021 Irrevocable Trust(3)
Common Stock	08/03/2026		S(1)		30,304	D	$26.714(5)	256,867	I	Coloma Family Trust(6)
Common Stock	08/03/2026		S(1)		1,604	D	$27.0853(7)	255,263	I	Coloma Family Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $26.97 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 4, 5, and 7 of this Form 4.

3. These securities are directly held by The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees.

4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.16 per share, inclusive.

5. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.005 to $26.985 per share, inclusive.

6. These securities are directly held by the Coloma Family Trust, for which the reporting person and his spouse serve as co-trustees.

7. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.19 per share, inclusive.

	/s/ Courtney Phillips, as attorney-in-fact	08/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)